Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01224236 · ClinicalTrials.gov registry record · Phase 2
Randomized Trial of Iron Supplementation to Prevent Anemia in Very-low-birth-weight Infants
A Phase 2 study of Anemia, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT01224236 is a Phase 2 study of Anemia that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 150 participants, below the 426-participant average among 72 other Anemia trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01224236, a Phase 2 study of Anemia, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if iron supplementation in addition to routine iron intake decreases the risk of developing anemia in preterm infants.
Conditions Studied
Interventions
- DRUG control
- DRUG Iron Supplement
Study Locations (1)
Texas
- Children's Memorial Hermann Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01224236
The ClinicalTrials.gov registry entry for NCT01224236 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 426-participant average among 72 other Anemia trials with a reported enrollment target (65% lower). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anemia appearing as the primary indexed condition, and to 2 interventions - of which control is the first listed.
NCT01224236 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01224236 about?
NCT01224236 is a clinical study titled "Randomized Trial of Iron Supplementation to Prevent Anemia in Very-low-birth-weight Infants". The purpose of this study is to determine if iron supplementation in addition to routine iron intake decreases the risk of developing anemia in preterm infants.
What is the current status of trial NCT01224236?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2010-07. Estimated completion is 2012-02.
What conditions does trial NCT01224236 study?
This clinical trial studies the following conditions: Anemia.
What interventions are being tested in trial NCT01224236?
The interventions under investigation include: control (DRUG), Iron Supplement (DRUG).
Who is sponsoring clinical trial NCT01224236?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01224236 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
Study of DISC-0974-201 in Participants With IBD and Anemia
RECRUITING · Phase 2
-
129Xe MRI Cardiopulmonary
RECRUITING · Phase 2
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Choline and Iron Deficiency
RECRUITING · Phase 2
-
Luspatercept for Clonal Cytopenias of Uncertain Significance
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.